Current issues in ER and HER2 testing by IHC in breast cancer
Top Cited Papers
- 1 May 2008
- journal article
- review article
- Published by Elsevier in Laboratory Investigation
- Vol. 21, S8-S15
- https://doi.org/10.1038/modpathol.2008.34
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breastJournal of Clinical Pathology, 2006
- HER2and Responsiveness of Breast Cancer to Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with TrastuzumabBreast Cancer Research and Treatment, 2005
- Bimodal Frequency Distribution of Estrogen Receptor Immunohistochemical Staining Results in Breast CancerAmerican Journal of Clinical Pathology, 2005
- Enhanced Accuracy and Reliability of HER-2/neu Immunohistochemical Scoring Using Digital MicroscopyAmerican Journal of Clinical Pathology, 2004
- No Rational Theory for Drug PricingJournal of Clinical Oncology, 2004
- Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH AssayAmerican Journal of Clinical Pathology, 2004
- HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survivalMolecular Diagnosis, 2000